These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 10602697)

  • 1. Design, synthesis, and evaluations of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinases.
    Sun L; Tran N; Liang C; Tang F; Rice A; Schreck R; Waltz K; Shawver LK; McMahon G; Tang C
    J Med Chem; 1999 Dec; 42(25):5120-30. PubMed ID: 10602697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases.
    Sun L; Tran N; Liang C; Hubbard S; Tang F; Lipson K; Schreck R; Zhou Y; McMahon G; Tang C
    J Med Chem; 2000 Jul; 43(14):2655-63. PubMed ID: 10893303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases.
    Sun L; Tran N; Tang F; App H; Hirth P; McMahon G; Tang C
    J Med Chem; 1998 Jul; 41(14):2588-603. PubMed ID: 9651163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dual inhibitor of platelet-derived growth factor beta-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells. A novel candidate for prevention of vascular remodeling.
    Waltenberger J; Uecker A; Kroll J; Frank H; Mayr U; Bjorge JD; Fujita D; Gazit A; Hombach V; Levitzki A; Böhmer FD
    Circ Res; 1999 Jul; 85(1):12-22. PubMed ID: 10400906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of vascular endothelial and platelet-derived growth factor receptor inhibitors on long-term cultures from normal human bone marrow.
    Dührsen U; Martinez T; Vohwinkel G; Ergün S; Sun L; McMahon G; Dürig J; Hossfeld DK; Fiedler W
    Growth Factors; 2001; 19(1):1-17. PubMed ID: 11678206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
    Haspel HC; Scicli GM; McMahon G; Scicli AG
    Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-1 beta upregulates cardiac expression of vascular endothelial growth factor and its receptor KDR/flk-1 via activation of protein tyrosine kinases.
    Maruyama K; Mori Y; Murasawa S; Masaki H; Takahashi N; Tsutusmi Y; Moriguchi Y; Shibazaki Y; Tanaka Y; Shibuya M; Inada M; Matsubara H; Iwasaka T
    J Mol Cell Cardiol; 1999 Mar; 31(3):607-17. PubMed ID: 10198191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of angiogenesis inhibitors on oestrogen-mediated endometrial endothelial cell proliferation in the ovariectomized mouse.
    Heryanto B; Lipson KE; Rogers PA
    Reproduction; 2003 Mar; 125(3):337-46. PubMed ID: 12611597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.
    Hennequin LF; Thomas AP; Johnstone C; Stokes ES; Plé PA; Lohmann JJ; Ogilvie DJ; Dukes M; Wedge SR; Curwen JO; Kendrew J; Lambert-van der Brempt C
    J Med Chem; 1999 Dec; 42(26):5369-89. PubMed ID: 10639280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bis(1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase.
    Mahboobi S; Teller S; Pongratz H; Hufsky H; Sellmer A; Botzki A; Uecker A; Beckers T; Baasner S; Schächtele C; Uberall F; Kassack MU; Dove S; Böhmer FD
    J Med Chem; 2002 Feb; 45(5):1002-18. PubMed ID: 11855980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis, antitumor evaluations and molecular modeling studies of novel 3,5-substituted indolin-2-one derivatives.
    Li HH; Zheng XH; Tan JZ; Chen LL; Liu H; Luo XM; Shen X; Lin LP; Chen KX; Ding J; Jiang HL
    Acta Pharmacol Sin; 2007 Jan; 28(1):140-52. PubMed ID: 17184594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications.
    Vajkoczy P; Thurnher A; Hirth KP; Schilling L; Schmiedek P; Ullrich A; Menger MD
    Oncologist; 2000; 5 Suppl 1():16-9. PubMed ID: 10804086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flk-1 as a target for tumor growth inhibition.
    Strawn LM; McMahon G; App H; Schreck R; Kuchler WR; Longhi MP; Hui TH; Tang C; Levitzki A; Gazit A; Chen I; Keri G; Orfi L; Risau W; Flamme I; Ullrich A; Hirth KP; Shawver LK
    Cancer Res; 1996 Aug; 56(15):3540-5. PubMed ID: 8758924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
    Laird AD; Vajkoczy P; Shawver LK; Thurnher A; Liang C; Mohammadi M; Schlessinger J; Ullrich A; Hubbard SR; Blake RA; Fong TA; Strawn LM; Sun L; Tang C; Hawtin R; Tang F; Shenoy N; Hirth KP; McMahon G; Cherrington
    Cancer Res; 2000 Aug; 60(15):4152-60. PubMed ID: 10945623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic and antitumor agents. Design, synthesis, and evaluation of novel 2-amino-4-(3-bromoanilino)-6-benzylsubstituted pyrrolo[2,3-d]pyrimidines as inhibitors of receptor tyrosine kinases.
    Gangjee A; Yang J; Ihnat MA; Kamat S
    Bioorg Med Chem; 2003 Nov; 11(23):5155-70. PubMed ID: 14604679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human uterine myometrial smooth muscle cell proliferation and vascular endothelial growth-factor production in response to platelet-derived growth factor.
    Taniguchi Y; Morita I; Kubota T; Murota S; Aso T
    J Endocrinol; 2001 Apr; 169(1):79-86. PubMed ID: 11250649
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased vascular endothelial growth factor 165 binding to kinase insert domain-containing receptor after infection of human endothelial cells by recombinant adenovirus encoding the Vegf(165) gene.
    Weisz A; Koren B; Cohen T; Neufeld G; Kleinberger T; Lewis BS; Flugelman MY
    Circulation; 2001 Apr; 103(14):1887-92. PubMed ID: 11294808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
    Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
    Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells.
    Kanno S; Oda N; Abe M; Terai Y; Ito M; Shitara K; Tabayashi K; Shibuya M; Sato Y
    Oncogene; 2000 Apr; 19(17):2138-46. PubMed ID: 10815805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.